Scientists have successfully reversed chronic liver disease in mice without altering their diet, offering a promising new direction for treating a condition affecting millions. The breakthrough centers on the removal of specific dysfunctional immune cells that drive damaging inflammation, a discovery that could lead to non-invasive therapies for a widespread public health concern.
The study identified a group of senescent macrophages, described as "zombie cells," as a key driver of fatty liver disease progression. These cells accumulate with age and in response to high cholesterol, entering a state where they stop functioning properly but resist death, causing significant inflammation and tissue damage. In experiments, when researchers removed these senescent cells from mice, existing liver damage was not just halted but completely reversed, even as the animals continued on an unhealthy diet.
Senior author Anthony Covarrubias emphasized the scale of the problem, noting that fatty liver disease is appearing in younger populations and is often driven by overnutrition and excess cholesterol. "Physiologically, macrophages can handle cholesterol metabolism," explained first author Ivan Salladay-Perez. "But in a chronic state, it's pathological... that excess cholesterol appears to be a major driver of the senescent macrophage population." The researchers found these cells in only 5% of younger mice but in 60-80% of older ones, illustrating how they accumulate over time.
The research team is now focused on translating this discovery into human treatments. Their immediate next step is to identify pharmaceutical compounds, known as senolytics, that can safely and selectively remove these damaging senescent macrophages without side effects. This approach offers hope for a future where a major chronic condition could be treated with targeted drugs, moving beyond current limited and often invasive management strategies.